DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Haloperidol vs. Risperidone in the Treatment of Aggression in Psychotic Inmates

Information source: University of Connecticut Health Center
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Psychosis; Aggression

Intervention: risperidone (Drug)

Phase: N/A

Status: Terminated

Sponsored by: University of Connecticut

Official(s) and/or principal investigator(s):
catherine f lewis, md, Principal Investigator, Affiliation: University of Connecticut Health Center

Summary

This study examines the efficacy of haldol versus risperdal in the treatment of aggression in psychotic prison inmates. It is hypothsized that risperdal will be more effective in decreasing aggression than haldol.

Clinical Details

Official title: Efficacy of Risperidone Versus Haloperidol in the Treatment of Aggression and Hostility in Psychotic Inmates

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria: age 18 or over, psychotic disorder diagnosed on SCID, inmate at

correctional facility for at least 2 weeks -

Exclusion Criteria: active withdrawal from substances of abuse, non-psychotic individuals, pregnant women, people unable to give informed consent, patients on mood stabilizers

-

Locations and Contacts

University of connecticut health center, Farmington, Connecticut 06030, United States
Additional Information

Starting date: July 2002
Last updated: October 12, 2006

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017